Table 4.
Clinical features and tumor characteristics of patients according to the rs12592697 polymorphism.
| CC (N = 111) | CT/TT (N = 195) | P | |
|---|---|---|---|
| Age | 53.2 ± 10.4 | 53.0 ± 11.1 | 0.90 |
| BMI | 28.2 ± 6.9 | 29.0 ± 6.7 | 0.36 |
| Menopausal status (n = 302) | |||
| Premenopausal | 31 (28.4%) | 70 (36.3%) | 0.04 |
| Perimenopausal | 12 (11.0%) | 8 (4.1%) | |
| Postmenopausal | 66 (60.6%) | 115 (59.6%) | |
| History of postmenopausal hormone therapy | 35/108 (32.4%) | 62/197 (31.5%) | 0.87 |
| Racial/Ethnic distribution | |||
| Non-Hispanic whites (N = 154) | 64/154 (41.6%) | 90/154 (59.6%) | 0.10 |
| Hispanic whites (N = 111) | 32/111 (28.8%) | 79/111 (71.2%) | **NHW vs. Hispanics only P = 0.03 |
| *Others (N = 41) | 15/41 (36.6%) | 26/41 (63.4%) | |
| Receptor status | |||
| ER | (N = 108) | (N = 185) | 0.04 |
| Positive | 85/108 (78.7%) | 125/185 (67.6%) | |
| Negative | 23/108 (21.3%) | 60/185 (32.4%) | |
| PR | (N = 137) | (N = 182) | 0.08 |
| Positive | 71/137 (66.4%) | 100/182 (54.9%) | |
| Negative | 36/137 (33.6%) | 82/182 (45.1%) | |
| HER2 | (N = 94) | (N = 177) | 0.50 |
| Positive | 23/94 (24.5%) | 37/177 (20.9%) | |
| Negative | 71/94 (75.5%) | 140/177 (79.1%) | |
| Triple negative | 19/107 (17.8%) | 38/191 (19.9%) | 0.65 |
| Progressive disease | 13/108 (12.0%) | 40/182 (22.0%) | 0.03 |
| Stage at diagnosis (n = 303) | 0.49 | ||
| Stage 0–II | 86/110 (78.2%) | 144/193 (74.6%) | |
| III–IV | 24/110 (21.8%) | 49/193 (25.4%) | |
| Estradiol (pg/ml) | 26.8 ± 37.3 | 24.3 ± 22.5 | 0.65 |
Formats of cell entries are mean ± SD or frequency/n (%), BMI, body mass index;
*
African-Americans, Native Americans, Asians, and multiracial. ER, Estrogen receptor; PR, progesterone receptor; HER2, Human epidermal growth factor receptor 2;
**
Comparison of allele/genotype frequency between NHW and Hispanics only by T-test. Bold values indicate that the p-value is statistically significant.